Lemercier Jean-Luc M's Form 4 filing
Edwards Lifesciences Corp (EW) · filed Mar 8, 2023
- Accession no.
- 0001225208-23-003597
- Filed
- Mar 8, 2023
- Trade date
- Mar 8, 2023
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $511.0K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lemercier Jean-Luc MCIK 0001710625 | Officer (CVP, EMEACLA and JAPAC) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 8, 2023 | Common Stock | MOption exerciseAcquired | +6,640 | $35.20 | +$233,728 | 175,514.87 | Direct | |
| Mar 8, 2023 | Common Stock | SSaleDisposed | −50 | $77.43 | −$3,871.5 | 175,464.87 | Direct | |
| Mar 8, 2023 | Common Stock | SSaleDisposed | −6,590 | $76.95F2 | −$507,100.5 | 168,874.87 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 8, 2023 | Common Stock | MOption exerciseDisposed | −6,640 | $0.00 | $0 | 13,280 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $76.43 to $77.36 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.